Shanghai Henlius Biotech Inc. is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding AG about selling them the rights to an experimental cancer drug, people familiar with the matter said.
An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. at least several hundred million dollars up front and then more in milestone payments down the line based on the drug’s performance, the people said, asking not to be identified because the discussions are private.
Negotiations are ongoing and Henlius could push for a higher figure as more data on the drug’s ...
